By Research and Markets (http://www.researchandmarkets.com/research/cn34lq/comparison_of) has announced the addition of the "Comparison of Innovative Drug R&D between China and India 2014" report to their offering.
The report, Comparison of Innovative Drug R&D between China and India, published by JZMed, Inc, a world-renowned market research firm specialized in pharmaceutical and biotechnology industries, has conducted so far the most complete and comprehensive comparisons between China and India in innovative drug research and development. It is designed to help the global drug R&D-focused companies better understand the similarities and differences in innovative drug R&D progress between China and India and the future development potentials of each country in this area, so that they could formulate the best strategies in the local markets.
The report first revealed the similarities and differences between these two countries in research and development of innovative medicines, including small molecule drugs, therapeutic proteins and antibodies, and vaccines as well as biosimilars. It reveals not only the current development situations of drug R&D in each country but also their current strengths and weaknesses and advantages and disadvantages in each area of the drug research and development. It provides a clear picture of the current progress of drug R&D in each country and their future growth potentials.
The report is a must-read book to all global pharmaceutical, biotechnology and financial investment companies that are interested in having a best position in either one of these two countries. It is also a valuable reference book to drug regulatory agencies and other government agencies that are involved in strategic planning for development of the pharmaceutical and biotechnology industries in their home country.
Key Topics Covered:
Executive Summary
- Current drug R&D infrastructure in China and India
- Innovative drug R&D in China and India - Key players and their pipelines
- R&D strategies and activities of multinational drug companies in China and India
- Comparison of future development potentials of innovative drug R&D between China and India
Chapter One - Current Drug R&D Infrastructure in China and India
1.1 Introduction
1.2 Current basic R&D infrastructure in China and India
1.3 Current states of biotechnology industry in China and India
1.4 Current key drug R&D forces in China and India
1.5 Current R&D funding situations in China and India
1.6 Current R&D spending levels of Chinese and Indian drug companies
Chapter Two - Innovative Drug R&D in China and India - Key Players and Their Pipelines
2.1 Introduction
2.2 Current overall states of drug R&D in China and India
2.3 Small molecule drug R&D in China and India - Major players, their capabilities and pipelines
2.4 MAb drug R&D in China and India - Major players, their capabilities and pipelines
2.5 Protein drug R&D in China and India - Major players, their capabilities and pipelines
2.6 Vaccine R&D in China and India - Major players, their capabilities and pipelines
2.7 Biosimilar R&D in China and India - Major players, their capabilities and pipelines
Chapter Three - R&D Strategies and Activities of Multinational Drug Companies in China and India
3.1 Introduction
3.2 China's and India's attractions to global drug companies
3.3 Current R&D strategies of global major pharma and biopharma companies in China and India
3.4 Multinational drug companies conducting drug R&D in China
3.5 Multinational drug companies conducting drug R&D in India
3.6 Analysis and comparison of R&D collaborations between multinational drug companies and Chinese and Indian companies
Chapter Four - Comparison of Future Development Potentials of Innovative Drug R&D between China and India
4.1 Introduction
4.2 Analysis of China's current strengths and weaknesses in innovative drug R&D
4.3 Analysis of India's current strengths and weaknesses in innovative drug R&D
4.4 Comparison of current strengths and weaknesses of China and India in innovative drug R&D
4.5 Innovative drug R&D supported by local governments
4.6 Analysis of future possible R&D strategies of global major pharma/biopharma companies in China and India
4.7 Comparison of future development potentials of innovative drug R&D between China and India
For more information visit http://www.researchandmarkets.com/research/cn34lq/comparison_of
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals
